Eli Lilly's migraine drug fails to prove superiority to Pfizer's | Reuters

Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023 after Eli Lilly and Co on Wednesday said it will cut list prices …

Do you trust this headline?

Based on recent headline ratings, 97% of this readership currently trusts the local media, which has an average score of 84% regionally and is currently trending positive.

97%

Media Trust Score97%